Laminin 511-E8 Fragments for Corneal Endothelial Cell Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human corneal endothelial cells are difficult to culture and regenerate, leading to challenges in corneal endothelial therapy and transplantation, particularly in Japan where there is a shortage of corneal donations and limited effectiveness of conventional treatments for conditions like bullous keratopathy.
Innovation Solution
The use of specific laminins, such as laminin 511-E8 fragments, to promote cell adhesion and proliferation of corneal endothelial cells, enhancing their therapeutic potential for corneal endothelial therapy by improving cell transplantation outcomes and healing of Descemet's membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional techniques are used for corneal endothelial therapy, then treatment options are limited, but therapeutic effectiveness is insufficient
Solution Approach 1:
Laminin 511-E8 fragments are used as intermediary substances to mediate between transplanted corneal endothelial cells and the host corneal stroma. The laminin fragments facilitate cell adhesion, survival, and integration by providing biochemical cues that bridge the gap between the graft and host tissue, thereby improving therapeutic effectiveness while maintaining treatment versatility
Solution Approach 2:
The invention changes the biochemical parameters of the transplantation environment by introducing specific laminin 511-E8 fragments. This modifies the extracellular matrix composition and cell adhesion properties, creating optimal conditions for corneal endothelial cell regeneration and improving treatment outcomes without limiting other therapeutic approaches
2Reliability
If corneal endothelial cells are transplanted without laminin, then procedure is simpler, but cell adhesion and proliferation are insufficient
Solution Approach 1:
Laminin 511-E8 fragments are applied to the corneal stroma surface before cell transplantation to pre-establish an adhesive substrate. This preliminary action prepares the implantation site with optimal biochemical properties, ensuring enhanced cell adhesion and proliferation while keeping the overall procedure relatively simple through a single additional treatment step
3Stability of the object's composition
If Descemet's membrane is not healed, then corneal structure remains unstable, but visual recovery is limited
Solution Approach 1:
Laminin 511-E8 fragments act as intermediary molecules that facilitate the healing and stabilization of Descemet's membrane. By promoting cell adhesion and tissue integration at the membrane level, the laminin fragments restore structural stability, which in turn enables better visual recovery through proper corneal architecture restoration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of laminin 511-E8 fragments results in near complete recovery from bullous keratopathy, reducing corneal thickness and achieving therapeutic effects previously unattainable with conventional techniques, demonstrating improved cell adhesion and functional recovery of corneal endothelial cells.
Implementation Method 1
Adhesion of injected cells to the substrate after 24 hours was compared for individuals to which cultured rabbit corneal endothelial cells were injected with a ROCK inhibitor Y-27632 (+) (100 μM) into the anterior chamber and individuals to which cells, laminin 511-E8 fragments (2.1 nM), and Y-27632 (+) (100 μM) were injected
Implementation Method 2
The use of specific laminins, such as laminin 511-E8 fragments, to promote cell adhesion and proliferation of corneal endothelial cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or a fragment of these.